A team of researchers from Cleveland Clinic Genomic Medicine share insights from an early set of 19,000 patients to receive immune checkpoint inhibitor treatments for colorectal cancer in the U.S.

Microba, one of Australia's leading biotechnology companies, developed the MetaPanel Metagenomic testing solution to help ...

HOLYOKE, Mass. (WWLP) – In honor of women’s history month, the Greater Holyoke YMCA hosted a panel discussion with women leaders who are positively impacting the community. This event ...

QIAGEN N.V. QGEN has secured FDA clearance for its QIAstat-Dx Gastrointestinal Panel 2 Mini B for clinical use, bolstering its syndromic testing portfolio in the United States. This marks the ...

The FDA has granted clearance to Qiagen’s QIAstat-Dx Gastrointestinal Panel 2 Mini B, expanding the company’s syndromic ...

QIAGEN has received FDA approval for its QIAstat-Dx Gastrointestinal Panel 2 Mini B, expanding its syndromic testing offerings for gastrointestin ...

These pathogens are identified as primary causes of gastrointestinal illnesses by the Infectious Diseases Society of America. The panel “complements” the QIAstat-Dx Gastrointestinal Panel 2 ...

Physicians are more likely to order respiratory pathogen testing since the COVID-19 pandemic, affecting testing rates and costs. The COVID-19 pandemic has had numerous effects on medical practice ...

U.S.A.I.D. Advertisement Supported by Organizations funded by the United States helped keep dangerous pathogens in check around the world. Now many safeguards are gone, and Americans may pay the ...

Qiagen (QGEN) announced that the FDA has cleared the QIAstat-Dx Gastrointestinal Panel 2 Mini B for clinical use. This marks Qiagen’s second FDA clearance of a QIAstat-Dx panel in 2025 ...